Arbutus Biopharma Corp.

Is Arbutus Biopharma Corp. technically bullish or bearish?

As of September 5, 2025, Arbutus Biopharma Corp. shows a bullish technical trend, supported by strong MACD and moving averages, with a 30.77% return over the past month compared to the S&P 500's 2.33%.

As of 5 September 2025, the technical trend for Arbutus Biopharma Corp. has changed from mildly bullish to bullish. The MACD is bullish on both weekly and monthly time frames, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a mildly bullish signal on the weekly chart and bullish on the monthly. However, the KST is bullish weekly but mildly bearish monthly, and the Dow Theory indicates no trend weekly while being mildly bullish monthly. <BR><BR>In terms of performance, the stock has returned 30.77% over the past month compared to the S&P 500's 2.33%, and it has a year-to-date return of 35.17% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish, supported by strong MACD and moving average indicators.

How big is Arbutus Biopharma Corp.?

As of Jun 18, Arbutus Biopharma Corp. has a market capitalization of 660.77 million and reported net sales of 6.40 million with a net loss of 76.58 million over the last four quarters.

As of Jun 18, Arbutus Biopharma Corp. has a market capitalization of 660.77 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 6.40 million for the latest four quarters, while the net profit for the same period was a loss of 76.58 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 97.37 million and total assets of 131.71 million.

What does Arbutus Biopharma Corp. do?

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing a cure for chronic hepatitis B virus (HBV) infection. It has a market cap of approximately $660.77 million and reported net sales of $2 million with a net loss of $25 million in March 2025.

Overview:<BR>Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a cure for chronic hepatitis B virus (HBV) infection, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 660.77 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.36 <BR>Return on Equity: -72.94% <BR>Price to Book: 8.35<BR><BR>Contact Details:<BR>Address: 701 Veterans Circle, WARMINSTER PA: 18974 <BR>Tel: 1 267 4690914 <BR>Website: http://www.arbutusbio.com/

Should I buy, sell or hold Arbutus Biopharma Corp.?

Who are in the management team of Arbutus Biopharma Corp.?

As of March 2022, the management team of Arbutus Biopharma Corp. includes Dr. Frank Torti (Independent Chairman), Mr. William Collier (President and CEO), and six independent directors: Mr. Daniel Burgess, Dr. Andrew Cheng, Mr. Richard Henriques, Dr. Keith Manchester, and Mr. James Meyers.

As of March 2022, the management team of Arbutus Biopharma Corp. includes the following individuals:<BR><BR>- Dr. Frank Torti, who serves as the Independent Chairman of the Board.<BR>- Mr. William Collier, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Daniel Burgess, who is an Independent Director.<BR>- Dr. Andrew Cheng, who is an Independent Director.<BR>- Mr. Richard Henriques, who is an Independent Director.<BR>- Dr. Keith Manchester, who is an Independent Director.<BR>- Mr. James Meyers, who is an Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors.